Home › Research › Risk genes beyond APOE
"Transformative Approaches to Alzheimer Disease Treatment: Current Progress and Future Direction”
Vandana Bhatia. Communications on Applied Nonlinear Analysis, 2025-04-24
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer's disease (AD) is a neurological condition that worsens over time and is characterised by tau tangles and amyloid plaques. Current medications mostly address symptoms, despite significant research advancement, leaving a demand for disease-modifying therapy unfulfilled. New treatment approaches target the genetic and molecular causes of AD by focussing on gene editing, specifically the CRISPR-Cas9 system. By specifically editing genes linked to disease, including APP, PSEN1, PSEN2, and APOE4, CRISPR-Cas9 aims to improve neuronal protection and lessen tau and amyloid-beta pathology. Base and prime editing are two recent developments in CRISPR technology that have increased therapeutic potential, decreased off-target effects, and improved editing specificity. In cellular and animal models, preclinical research shows that it is effective in repairing mutations, modifying gene expression, and lowering the synthesis of neurotoxic proteins. Adeno-associated viruses (AAVs) and lipid nanoparticles are two delivery systems that have been created to get across the blood-brain barrier's obstacles. Clinical use is nevertheless hampered by concerns about long-term safety, distribution efficiency, and ethical issues, despite encouraging results. CRISPR-Cas9's combination with immunotherapy and artificial intelligence has created new opportunities for precision medicine by providing specialised methods to address the pathological and genetic characteristics of AD. With its potential to shift AD treatment from symptomatic management to curative approaches, this review focusses on the advancements, difficulties, and prospects of CRISPR-Cas9 in AD therapies. To advance CRISPR-based medicines into clinical practice, ongoing innovation in gene-editing technologies, delivery methods, and ethical frameworks will be essential
Key findings
- Current medications mostly address symptoms, despite significant research advancement, leaving a demand for disease-modifying therapy unfulfilled.
- Clinical use is nevertheless hampered by concerns about long-term safety, distribution efficiency, and ethical issues, despite encouraging results.
Why it matters
This review discusses CRISPR-Cas9 and newer editing approaches targeting genes such as APP, PSEN1, PSEN2 and APOE4, with preclinical evidence in cellular and animal models. It notes that clinical use is hampered by concerns about long-term safety, delivery efficiency and ethical issues, so no treatment or cure is yet established.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 25 of the 93 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Communications on Applied Nonlinear Analysis) |
| Journal's citation record | 0 / 4 | Communications on Applied Nonlinear Analysis: journal h-index 10 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 25 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 25 of the 93 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.52783/cana.v32.5141
- Original source →
- Free full text: Communications on Applied Nonlinear Analysis →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Bhatia, V. (2025). "Transformative Approaches to Alzheimer Disease Treatment: Current Progress and Future Direction”. Communications on Applied Nonlinear Analysis. https://doi.org/10.52783/cana.v32.5141
Vancouver
Bhatia V. "Transformative Approaches to Alzheimer Disease Treatment: Current Progress and Future Direction”. Communications on Applied Nonlinear Analysis. 2025. doi:10.52783/cana.v32.5141.
BibTeX
@article{bhatia2025-b059f7db,
author = {Bhatia, Vandana},
title = {{"Transformative Approaches to Alzheimer Disease Treatment: Current Progress and Future Direction”}},
journal = {Communications on Applied Nonlinear Analysis},
year = {2025},
doi = {10.52783/cana.v32.5141},
url = {https://doi.org/10.52783/cana.v32.5141}
}
Related studies in Risk genes beyond APOE
Also in Risk genes beyond APOE
98 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.